Sorafenib
- Generic Name
- Sorafenib
- Brand Names
- Nexavar, Sorafenib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16ClF3N4O3
- CAS Number
- 284461-73-0
- Unique Ingredient Identifier
- 9ZOQ3TZI87
- Background
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to ...
- Indication
Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
In the US, it is also indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.
- Associated Conditions
- Advanced Renal Cell Carcinoma, Angiosarcoma, Gastrointestinal Stromal Tumor (GIST), Leiomyosarcoma (LMS), Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally recurrent radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC)
- Associated Therapies
- -
Efficacy Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine Tumors
- First Posted Date
- 2008-01-31
- Last Posted Date
- 2019-02-19
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 22
- Registration Number
- NCT00605566
- Locations
- 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250
- Conditions
- Interventions
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2013-12-02
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 26
- Registration Number
- NCT00602862
- Locations
- 🇳🇱
Radboud University Nijmegen Medical Center, Nijmegen, Gelderland, Netherlands
Sorafenib as a Second Line Treatment in Patients With Advanced or Metastatic Gastric Cancer
- First Posted Date
- 2008-01-16
- Last Posted Date
- 2009-07-07
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 5
- Registration Number
- NCT00595985
- Locations
- 🇨🇳
Fudan University Cancer Hospital, ShangHai, Shanghai, China
PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-01-09
- Last Posted Date
- 2015-06-08
- Lead Sponsor
- Thomas Olencki
- Target Recruit Count
- 1
- Registration Number
- NCT00589550
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC
- First Posted Date
- 2007-12-18
- Last Posted Date
- 2017-02-15
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 19
- Registration Number
- NCT00576056
- Locations
- 🇺🇸
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
Sorafenib and Bevacizumab in Combination With Paclitaxel in Patients With Solid Tumors
- First Posted Date
- 2007-12-12
- Last Posted Date
- 2017-09-25
- Lead Sponsor
- Safi Shahda
- Target Recruit Count
- 27
- Registration Number
- NCT00572078
- Locations
- 🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States
Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-10-16
- Last Posted Date
- 2013-04-01
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 45
- Registration Number
- NCT00544167
- Locations
- 🇺🇸
Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
🇺🇸Integrated Community Oncology Network, Jacksonville, Florida, United States
🇺🇸Consultants in Blood Disorders and Cancer, Louisville, Kentucky, United States
Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme
- Conditions
- Interventions
- First Posted Date
- 2007-10-16
- Last Posted Date
- 2016-09-01
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 47
- Registration Number
- NCT00544817
- Locations
- 🇺🇸
Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States
🇺🇸Methodist Cancer Center, Omaha, Nebraska, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
Sorafenib and Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative Intent
- First Posted Date
- 2007-10-16
- Last Posted Date
- 2014-10-02
- Lead Sponsor
- Spanish Oncology Genito-Urinary Group
- Target Recruit Count
- 10
- Registration Number
- NCT00544609
- Locations
- 🇪🇸
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
🇪🇸Hospital Clínic i Provincial de Barcelona, Barcelona, Spain
🇪🇸Institut Català d' Oncología, Barcelona, Spain
Bevacizumab in Multiple Phase I Combinations
- Conditions
- Interventions
- First Posted Date
- 2007-10-15
- Last Posted Date
- 2020-06-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 343
- Registration Number
- NCT00543504
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.